
## Marcel Smid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7470639/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression. JCO Precision Oncology, 2022, 6, e2100190.	3.0	5
2	Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer. Cancers, 2022, 14, 753.	3.7	1
3	Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 5080.	4.1	2
4	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. Scientific Reports, 2021, 11, 7259.	3.3	20
5	Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients. Cancers, 2021, 13, 1903.	3.7	1
6	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer Journal of Clinical Oncology, 2021, 39, 3545-3545.	1.6	0
7	Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. Biology, 2021, 10, 768.	2.8	1
8	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668.	12.8	91
9	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. Molecular Oncology, 2021, 15, 3348-3362.	4.6	3
10	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications, 2021, 12, 574.	12.8	39
11	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA–minus RNA sequencing data. GigaScience, 2021, 10, .	6.4	10
12	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. Clinical Cancer Research, 2020, 26, 505-517.	7.0	26
13	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271.		29
14	Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction. BMC Cancer, 2020, 20, 1217.	2.6	10
15	Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression. Oncogene, 2020, 39, 4118-4131.	5.9	19
16	ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers, 2020, 12, 802.	3.7	20
17	Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. Scientific Reports, 2020, 10, 22292.	3.3	11
18	Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer. Biomarkers in Medicine, 2019, 13, 841-850.	1.4	3

#	Article	IF	CITATIONS
19	Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes. Nature Communications, 2019, 10, 2983.	12.8	58
20	A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Research, 2019, 21, 77.	5.0	48
21	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. Cancers, 2019, 11, 1212.	3.7	21
22	Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Research, 2019, 21, 109.	5.0	94
23	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nature Genetics, 2019, 51, 1450-1458.	21.4	250
24	An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer. Scientific Reports, 2019, 9, 13308.	3.3	15
25	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	5.5	85
26	Molecular Comparison of Imatinib-NaÃ <sup>-</sup> ve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. Cancers, 2019, 11, 882.	3.7	9
27	MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS ONE, 2019, 14, e0216400.	2.5	54
28	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nature Communications, 2019, 10, 1749.	12.8	46
29	Co-regulated gene expression of splicing factors as drivers of cancer progression. Scientific Reports, 2019, 9, 5484.	3.3	22
30	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. International Journal of Cancer, 2019, 145, 1083-1089.	5.1	27
31	A tale on rabbit ears and pan-handles, the rings that rule all. EBioMedicine, 2019, 49, 17-18.	6.1	0
32	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research, 2019, 21, 151.	5.0	30
33	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations. European Journal of Surgical Oncology, 2019, 45, 691-698.	1.0	4
34	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3397-3408.	7.0	68
35	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. Acta Neuropathologica, 2018, 135, 581-599.	7.7	63
36	Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Scientific Reports, 2018, 8, 5242.	3.3	33

#	Article	IF	CITATIONS
37	Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. Cancers, 2018, 10, 500.	3.7	7
38	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. BMC Bioinformatics, 2018, 19, 236.	2.6	105
39	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers, 2018, 10, 134.	3.7	18
40	Functional <i>Ex Vivo</i> Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research, 2018, 24, 6277-6287.	7.0	53
41	Epithelial–Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. Cancer Research, 2018, 78, 4671-4679.	0.9	41
42	MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. Oncotarget, 2018, 9, 24335-24346.	1.8	11
43	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nature Genetics, 2017, 49, 341-348.	21.4	75
44	Proteomic characterization of microdissected breast tissue environment provides a proteinâ€level overview of malignant transformation. Proteomics, 2017, 17, 1600213.	2.2	7
45	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research, 2017, 77, 3814-3822.	0.9	76
46	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Scientific Reports, 2017, 7, 2099.	3.3	33
47	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. European Journal of Cancer, 2017, 75, 33-40.	2.8	22
48	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	2.5	14
49	The advantage of laser apture microdissection over whole tissue analysis in proteomic profiling studies. Proteomics, 2016, 16, 1474-1485.	2.2	38
50	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer, 2016, 16, 34.	2.6	35
51	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
52	Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. Scientific Reports, 2016, 6, 32027.	3.3	19
53	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	12.8	119
54	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Letters, 2016, 376, 104-109.	7.2	22

#	Article	IF	CITATIONS
55	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer, 2016, 16, 123.	2.6	25
56	4â€protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology, 2016, 10, 24-39.	4.6	31
57	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget, 2016, 7, 59058-59069.	1.8	37
58	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. Oncotarget, 2016, 7, 3098-3110.	1.8	26
59	Mitochondrial DNA content in breast cancer: Impact on <i>in vitro</i> and <i>in vivo</i> phenotype and patient prognosis. Oncotarget, 2016, 7, 29166-29176.	1.8	33
60	Global proteomic characterization of microdissected estrogen receptor positive breast tumors. Data in Brief, 2015, 5, 399-402.	1.0	1
61	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	5.2	42
62	Understanding drugs in breast cancer through drug sensitivity screening. SpringerPlus, 2015, 4, 611.	1.2	11
63	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS ONE, 2015, 10, e0144097.	2.5	6
64	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
65	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Molecular Oncology, 2015, 9, 920-932.	4.6	37
66	Proper genomic profiling of ( <i>BRCA1</i> â€mutated) basalâ€like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Molecular Oncology, 2015, 9, 877-888.	4.6	16
67	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Letters, 2015, 362, 36-44.	7.2	41
68	Predicting paclitaxel-induced neutropenia using the DMET platform. Pharmacogenomics, 2015, 16, 1231-1241.	1.3	15
69	Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas. PLoS ONE, 2015, 10, e0121361.	2.5	14
70	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	2.5	319
71	Response. Journal of the National Cancer Institute, 2014, 106, dju254-dju254.	6.3	0
72	Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways. Cancer Research, 2014, 74, 2936-2945.	0.9	82

#	Article	IF	CITATIONS
73	DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Molecular Oncology, 2014, 8, 458-468.	4.6	46
74	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer Journal of Clinical Oncology, 2014, 32, 11017-11017.	1.6	0
75	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Research, 2013, 15, R33.	5.0	170
76	Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma. Cell, 2013, 154, 1060-1073.	28.9	359
77	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052 Journal of Clinical Oncology, 2013, 31, 10573-10573.	1.6	2
78	A pharmacogenetic model predicting low paclitaxel clearance based on the DMET platform Journal of Clinical Oncology, 2013, 31, 2597-2597.	1.6	0
79	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Research and Treatment, 2012, 132, 439-448.	2.5	37
80	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Research and Treatment, 2011, 128, 23-30.	2.5	83
81	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011, 17, 3600-3618.	7.0	207
82	Subtypes of Breast Cancer Show Preferential Site of Relapse. Cancer Research, 2008, 68, 3108-3114.	0.9	674
83	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13021-13026.	7.1	374
84	Genes Associated With Breast Cancer Metastatic to Bone. Journal of Clinical Oncology, 2006, 24, 2261-2267.	1.6	278